Real-life use of ceftobiprole for severe infections in a French intensive care unit
-
Published:2024-02
Issue:1
Volume:54
Page:104790
-
ISSN:2666-9919
-
Container-title:Infectious Diseases Now
-
language:en
-
Short-container-title:Infectious Diseases Now
Author:
Bellut HugoORCID,
Arrayago Marine,
Amara Marlène,
Roujansky ArianeORCID,
Micaelo MaitéORCID,
Bruneel Fabrice,
Bedos Jean-Pierre
Subject
Infectious Diseases
Reference28 articles.
1. Binding of Ceftobiprole and Comparators to the Penicillin-Binding Proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae;Davies;Antimicrob Agents Chemother,2007
2. In Vitro and In Vivo Properties of Ro 63–9141, a Novel Broad-Spectrum Cephalosporin with Activity against Methicillin-Resistant Staphylococci;Hebeisen;Antimicrob Agents Chemother,2001
3. Antimicrobial activity of ceftobiprole, a novel anti–methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005–2006);Fritsche;Diagn Microbiol Infect Dis,2008
4. Structural Insights into the Anti-methicillin-resistant Staphylococcus aureus (MRSA) Activity of Ceftobiprole;Lovering;J Biol Chem,2012
5. Murthy B, Schmitt-Hoffmann A. Pharmacokinetics and Pharmacodynamics of Ceftobiprole, an Anti-MRSA Cephalosporin with Broad-Spectrum Activity: Clin Pharmacokinet 2008;47:21–33. https://doi.org/10.2165/00003088-200847010-00003.